AUG 19, 2026 · PHASE 3 TRIAL
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
ClinicalTrials.gov
This is a clinical trial registry record describing an active Phase 3 study with no results posted; the planned design is sound but efficacy and safety outcomes remain unreported.
Reported
Planned enrollment740
Study phasePhase 3
Primary endpoint 1Progression-free Survival Based on Blinded…